Skip to main content
. 2023 Jul 20;24(14):11703. doi: 10.3390/ijms241411703

Table 1.

Characteristics of the study population.

Subjects (n = 16)
Sex (M:F) 4:12
Age (median [IQR]) 27.5 [24.8–34.3]
Vaccine manufacturer
  Pfizer 9
  Moderna 7
Race
  White/Caucasian 9
  Asian 6
  Unspecified 1
Antibiotic intake (past 3 months) 2
Probiotic intake (past 2 weeks and/or currently) 2
Blood sample collected for IgG titer post-dose 2 14
Matching stool samples collected at baseline, post-dose 1, and post-dose 2 16